The ELISAs revealed that the plasma levels of LAMC2 were significantly higher in pancreatic cancer patients compared to healthy donors, both in the training set and in the validation set (p < 0.0001) (Figure 3A). This evidence concerns the gene LAMC2 and familial pancreatic carcinoma.